Table 1.
Selected clinical trials with expanded allogeneic NK cells.
| Diseases | Status | Phase of trials | Cell product | Combined therapy | Institute | ClinicalTrials.gov Identifier |
|---|---|---|---|---|---|---|
| Hepatocellular carcinoma | Ongoing | Phase 2 | Ex vivo-expanded NK cells | None | Samsung Medical Center, Korea | NCT02008929 |
| Lymphoma and solid tumors | Completed | Phase 1 | Ex vivo-expanded NK cells | None | Seoul National University Hospital, Korea | NCT01212341 |
| High-risk solid tumors | Ongoing | Phase 2 | Ex vivo-expanded NK cells | Haploidentical HSCT, RIC, and IL-2 | Samsung Medical Center, Korea | NCT01807468 |
| Non-B lineage hematologic malignancies and solid tumors | Completed | Phase 1 | Ex vivo-expanded haploidentical NK cells | Chemotherapy and IL-2 | St. Jude Children’s Research Hospital, USA | NCT00640796 |
| Hematological malignancies | Ongoing | Phase 1 | IL-2-activated NK cells | Haploidentical HSCT and RIC | Institut Paoli-Calmettes, France | NCT01853358 |
| Multiple myeloma | Ongoing | Phase 1/2 | Ex vivo-expanded haploidentical NK cells | Autologous HSCT and chemotherapy | University Hospital, Basel, Switzerland | NCT01040026 |
| Leukemia and myeloproliferative disease | Ongoing | Phase 1/2 | Ex vivo-expanded NK cells | Haploidentical HSCT, TBI, and chemotherapy | M.D. Anderson Cancer Center, USA | NCT01904136 |
| ALL | Ongoing | Phase 2 | K562-mb15-41BBL and IL-2-stimulated NK cells | Haploidentical HSCT and chemotherapy | National University Health System, Singapore | NCT01974479 |
| AML and ALL | Ongoing | Phase 1/2 | Ex vivo-expanded NK cells | Haploidentical HSCT | Asan Medical Center, Korea | NCT01795378 |
| Relapsed/refractory pediatric acute leukemia | Ongoing | Phase 2 | Activated and expanded NK cells | Haploidentical HSCT and salvage chemotherapy | Hospital Universitario La Paz, Spain | NCT02074657 |
| Myelodysplastic syndrome and leukemia | Completed | Phase 1/2 | IL-2-activated NK cells | Haploidentical HSCT, chemotherapy, and IL-2 | M.D. Anderson Cancer Center, USA | NCT00402558 |
| Leukemia | Completed | Phase 2 | IL-2-activated NK cells | Chemotherapy and IL-2 | Masonic Cancer Center, University of Minnesota, USA | NCT00274846 |
| Relapsed/refractory pediatric T cell leukemia and lymphoma | Ongoing | Phase 1/2 | Activated and expanded NK cells | Salvage chemotherapy | Hospital Infantil Universitario Niño Jesús, Madrid, Spain | NCT01944982 |
| Leukemia | Ongoing | Phase 1/2 | mbIL21-expanded haploidentical NK cells | Chemotherapy | M.D. Anderson Cancer Center, USA | NCT01787474 |
| Acute leukemia and myelodysplastic syndrome | Ongoing | Phase 1 | K562-mb15-41BBL and IL-2-stimulated NK cells | Immunosuppressive therapy and IL-2 | National University Hospital, Singapore | NCT02123836 |
HSCT, hematopoietic stem cell transplantation; RIC, reduced-intensity conditioning; ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; TBI, total body irradiation.